WO2005035571A1 - 新規の糖タンパク質及びそれを含有する医薬組成物 - Google Patents
新規の糖タンパク質及びそれを含有する医薬組成物 Download PDFInfo
- Publication number
- WO2005035571A1 WO2005035571A1 PCT/JP2004/015057 JP2004015057W WO2005035571A1 WO 2005035571 A1 WO2005035571 A1 WO 2005035571A1 JP 2004015057 W JP2004015057 W JP 2004015057W WO 2005035571 A1 WO2005035571 A1 WO 2005035571A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glycoprotein
- recovery
- activity
- present
- fraction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/375—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Basidiomycetes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- Novel glycoprotein and pharmaceutical composition containing the same
- the present invention relates to a novel glycoprotein and a pharmaceutical composition containing the same, for example, a novel immunopotentiator, a stress load recovery promoter, or an antitumor agent.
- a novel immunopotentiator, stress load recovery promoter, or antitumor agent of the present invention, or the novel glycoprotein of the present invention can be administered in various forms that can be administered as a pharmaceutical, for example, health food (preferably a functional food). Foods) or feeds in the form of food and drink.
- the above-mentioned foods include beverages.
- oral hygiene compositions for example, those which are temporarily contained in the mouth, but which are mostly exhaled from the mouth, such as dentifrices, mouthwashes, chewing gums, or gargles, or It can also be given in the form of an inhalant which is inhaled through the nose.
- the immunopotentiating activity in the present specification includes antitumor activity.
- Patent Documents 1 and 2 disclose Matsutake mushrooms. Discloses various antitumor substances.
- the above-mentioned Patent Document 1 discloses that emitanin 5-A, emitanin 5-B, and emitanin 5-- also obtained by extracting and purifying a liquid culture of Matsutake mycelium with hot water or a dilute alkaline solution, and also extracting and refining an extractable liquid. It is disclosed that C and Emitanin 5-D have an inhibitory effect on the proliferation of sarcoma 180 cells.
- the present inventors have found that the matsutake hot water extract, the matsutake alkali solution extract, or the anion-exchange resin adsorbed fraction of the matsutake hot water extract or the matsutake alkali solution extract have immunopotentiating activity. (Patent Document 3).
- Patent Document 4 The partially purified fraction described in Patent Document 4 differs from a known fraction (for example, an anion-exchange resin-absorbed fraction described in Patent Document 3) in physicochemical properties. It is a fraction.
- Patent Document 1 Japanese Patent Publication No. 57-1230
- Patent Document 2 Patent No. 2767521
- Patent Document 3 International Publication No. WO01Z49308 pamphlet
- Patent Document 4 International Publication No.WO03Z070264 pamphlet
- the present inventor has attempted to purify the active substance contained in the extract or fraction derived from the mushroom having the immunopotentiating activity and the Z or stress load recovery promoting activity. Isolation as a single peak was not trivial in terms of critical properties (especially glycoproteins). However, when the molecular weight fractionation operation was combined after ion exchange separation, the compound having immunopotentiating activity, stress load recovery promoting activity, and antitumor activity was successfully isolated as a single peak. Newly found it to be a new glycoprotein. The present invention is based on such findings.
- an object of the present invention is to provide a novel glycoprotein useful as an active ingredient of an immunopotentiator, an agent for promoting recovery from stress, and Z or an antitumor agent, and further provide a novel glycoprotein containing the same.
- a pharmaceutical composition for example, an immunopotentiator, an agent for promoting recovery from stress, or an antitumor agent.
- the object of the present invention is to provide a glycoprotein having the following properties according to the present invention:
- the present invention provides (1) a step of extracting Matsutake with an alkaline solution or hot water, (2) a step of adsorbing the obtained extract to an anion exchange resin,
- a glycoprotein that can be prepared by a production method comprising:
- the present invention also relates to a pharmaceutical composition containing the glycoprotein and a pharmaceutically or veterinarily acceptable carrier or diluent.
- the present invention relates to an immunopotentiator, a stress load recovery promoter, or an antitumor agent, comprising the glycoprotein as an active ingredient.
- the present invention also relates to a method for enhancing immunity, which comprises administering the glycoprotein to a subject requiring immunity in an effective amount.
- the present invention relates to a method for promoting the recovery of stress load, comprising administering the glycoprotein to a subject in need of promoting the recovery of stress load in an effective amount.
- the present invention also relates to a method for treating or preventing a tumor, comprising administering the glycoprotein to a subject in need of the treatment or prevention of the tumor in an effective amount.
- the present invention provides an immunopotentiator or an immunopotentiator pharmaceutical composition, a stress load recovery / accelerating agent or a pharmaceutical composition for promoting stress load recovery, or an antitumor agent or an antitumor drug composition of the glycoprotein.
- an immunopotentiator or an immunopotentiator pharmaceutical composition for use in manufacturing.
- the immunopotentiator of the present invention can enhance the immunity of a subject requiring immunity enhancement. Further, according to the stress load recovery promoter of the present invention, recovery against stress load can be promoted. Further, according to the antitumor agent of the present invention, a tumor can be treated or prevented.
- the glycoprotein of the present invention is useful as an active ingredient of the above-mentioned immunopotentiator, stress load recovery promoter, or antitumor agent.
- the glycoprotein of the present invention has the following properties.
- Protein content and carbohydrate content 38.42 gZmg when calculated based on the amount of amino acids obtained by hydrolysis of the glycoprotein of the present invention. In addition, it was 628.72 / zgZmg when calculated based on the amount of monosaccharide obtained by hydrolysis of the glycoprotein of the present invention.
- the ratio of carbohydrate to protein is 16.4: 1.0.
- Amino acid thread aspartic acid and asparagine 9.65 mol%, threonine 6.15mo 1%, serine 6.83mol%, glutamic acid and glutamine 10.19mol%, glycine 8.74mol%, alanine 9.84mol%, norin 6.94mol %, 1 / 2-cystine 0.15mol%, methionine 1.31mol%, isoleucine 5.47mol%, leucine 9.55mol%, tyrosine 2.64mol%, hu-leualanine 4.09mol%, lysine 4.99mol%, histidine 1.97mol%, Arginine 5.00 mol%, tryptophan 1.17 mol%, and proline 5.33 mol%
- Neutral sugar composition glucose 561.45 ⁇ gZmg, mannose 16.68 ⁇ g / mg, galactose 42.65 ⁇ gZmg, and fucose 9.57 ⁇ gZmg.
- Xylose is below the detection limit.
- Amino sugar composition Darcosamine 0.36 gZmg. Mannosamine is below the detection limit.
- Circular dichroism analysis shows the spectrum shown in FIG.
- the glycoprotein of the present invention shows the spectrum shown in FIG.
- the spectrum shown in FIG. 9 is shown when the protein strength of the present invention is also removed by hydrazine treatment.
- UV ultraviolet spectroscopy
- the origin of the glycoprotein of the present invention is not particularly limited as long as it exhibits the above-mentioned properties.
- matsutake power can also be separated.
- Examples of the Matsutake mushroom include a natural fruit body or mycelium of Matsutake or a fungus mycelium or a culture (Broth) of Matsutake obtained by culture.
- Examples of the Matsutake mushroom used for cultivation include Matsutake FERM BP-7304 strain described in International Publication WO02Z30440 pamphlet. The above Matsutake FER M BP-7304 strain was obtained from the National Institute of Advanced Industrial Science and Technology, Patent Organism Depositary Center [formerly, National Institute of Advanced Industrial Science and Technology, Institute of Biotechnology and Industrial Technology (address: ⁇ 305-8566, Tsukuba East, Ibaraki, Japan 1) Chome No. 1 1 Chuo No. 6)] and deposited on September 14, 2000.
- This Matsutake FERM BP-7304 strain was obtained by subcutting the fungus body of Tricholoma matsutake CM6271 strain collected from Kameoka, Kyoto Prefecture, and culturing it in a test tube to obtain a mycelium subcultured strain. Maintained at the Biomedical Research Institute, Chemical Industry Co., Ltd.
- the glycoprotein of the present invention is not limited to the following operations. For example, a step of extracting Matsutake with an alkaline solution or hot water (hereinafter, referred to as an extraction step), A step of adsorbing on an anion exchange resin (hereinafter referred to as an anion exchange resin adsorbing step),
- a step of eluting the adsorbed fraction from the anion exchange resin with a suitable eluent (hereinafter, referred to as an elution step);
- a predetermined fraction eluted under the following elution conditions is fractionated by gel filtration to obtain a fraction having a molecular weight of 50 to 70 kDa (hereinafter, referred to as a gel filtration fractionation step).
- glycoprotein of the present invention not only contains the glycoprotein prepared by the above-mentioned production method, but also contains A glycoprotein prepared by a method other than the above-mentioned method is also included as long as it has the same properties as the prepared glycoprotein.
- the temperature of the hot water is preferably 60-100 ° C, more preferably 80-98 ° C.
- the extraction is preferably performed with stirring or shaking so that the extraction efficiency is improved.
- the extraction time is determined, for example, by the state of the mushroom (ie, the state of the fruit body, mycelium, or the culture, or the state of processing when it is processed into a crushed or powdered state). It can be appropriately determined according to the temperature of hot water, the presence or absence of stirring or shaking, or conditions, but it is usually 1 to 16 hours, and preferably 2 to 3 hours.
- the alkaline solution is not limited to this.
- a hydroxide of an alkali metal eg, sodium or potassium
- An aqueous solution of sodium acid oxide can be used.
- the pH of the alkaline solution is preferably from 8 to 13, more preferably from 9 to 12.
- the alkaline solution extraction step is preferably performed at 0-20 ° C, more preferably at 0-15 ° C.
- the extract obtained in the alkali extraction step can be subjected to a neutralization treatment and used in the next anion exchange resin adsorption step.
- the extract obtained in the extraction step in a state in which insolubles are present, can be used as it is in the next anion exchange resin adsorption step, after removing insolubles, or after removing insolubles. It is preferable to remove the low-molecular-weight fraction in the extract, and then use it in the next anion-exchange resin adsorption step. For example, centrifugation of an extract containing insolubles removes the insolubles, and only the resulting supernatant can be used in the next anion exchange resin adsorption step.
- the supernatant obtained by centrifuging an extract containing insolubles is dialyzed to remove a low molecular weight fraction (preferably a fraction having a molecular weight of 3500 or less), and then the next anion exchange step is performed. It can be used in the fat adsorption step.
- the extract obtained in the extraction step may be subjected to a degreasing step before being used in the next anion exchange resin adsorption step.
- this degreasing step and the insoluble matter and Z or The low-molecular-weight fraction removal step can be performed by either one or both.
- the organic solvent used in the degreasing step for example, a fat-soluble organic solvent (for example, chloroform, methanol, ether, ethanol, ethyl acetate, or hexane, etc.) or a mixture thereof (for example, chloroform and Mixed solution with methanol), and a mixed solution of clog form and methanol is preferred.
- a mixed solution of black form and methanol is used as the organic solvent, the mixture ratio [black form: methanol (v / v)] is, for example, 10: 1 to 1:10. be able to.
- the degreasing step is preferably performed at a temperature of 15-30 ° C.
- anion exchange resin that can be used in the anion exchange resin adsorption step
- a known anion exchange resin can be used.
- getylaminoethyl (DEAE) cellulose or triethylammonium Oethyl (TEAE) cellulose can be mentioned.
- the eluent used in the elution step can be appropriately determined according to the type of anion exchange resin used in the anion exchange resin adsorption step, and examples thereof include an aqueous sodium chloride solution. Can be.
- the fractions eluted in the elution step the fraction eluted under the following elution conditions (for example, fraction B in Example 2 described later) can be used in the next gel filtration fractionation step.
- a column packed with DEAE TOY OPEARL PAK 650M ( ⁇ 22 mm, h20 cm)] is used as the anion exchange resin, and the sample to be adsorbed is a 50 mmol ZL-Tris-HC1 buffer solution (pH 7.2).
- linear gradient elution of eluate A (50 mmol ZL-Tris-HC1 buffer) and eluate B (50 mmol ZL-Tris-HC1 buffer containing 1 mol ZL sodium chloride) is performed. It is performed at a flow rate of 5 mL Zmin, and 12 minutes to 15 minutes (the fraction eluted at a liquid volume of 15111 can be used for the next gel filtration fractionation step.
- the gel filtration fractionation step can be carried out according to a conventional method, and by obtaining a fraction having a molecular weight of 50 to 70 kDa (for example, a fraction B-1-2 in Example 2 described later), the present invention can be carried out. A fraction containing the bright glycoprotein as a single peak can be obtained.
- Gel filtration The over-fractionation step uses multiple (for example, two) gel filtration columns with different fractionation ranges. It can be carried out in a plurality of stages (for example, two stages), for example, using a gel filtration column having a molecular weight range of 1 ⁇ 10 3 —1 ⁇ 103 ⁇ 4a, and molecular weight fractionated by the gel filtration column.
- the fraction of 10 kDa or more was subsequently applied to a gel filtration column having a fractionation range of 4 ⁇ 10 4 —2 ⁇ 10 7 Da, and a molecular weight of 50 — A 70 kDa fraction (eg, fraction B-1-2 in Example 2 described below) can be obtained.
- the pharmaceutical composition of the present invention particularly, the immunopotentiator, the stress load recovery promoter or the antitumor agent of the present invention contains the glycoprotein of the present invention as an active ingredient.
- the immunopotentiator, stress load recovery promoter, or antitumor agent of the present invention is a general carrier or diluent that is pharmaceutically or veterinarily acceptable for the glycoprotein of the present invention as an active ingredient.
- it can be administered to animals, preferably mammals (particularly humans).
- the composition of the present invention preferably a pharmaceutical composition
- the immunopotentiating composition of the present invention preferably an immunopotentiating pharmaceutical composition
- the composition for promoting the recovery of stress load preferably the pharmaceutical composition for promoting the recovery of stress load
- an antitumor composition preferably an antitumor drug composition
- the glycoprotein of the present invention which is an active ingredient in the immunopotentiator of the present invention, has immunopotentiating activity.
- the immunopotentiating activity includes, for example, various activities described in WO03Z070264 pamphlet, such as antitumor activity [for example, prolonging survival time in cancer-bearing individuals, antigen-tumorigenic activity (particularly, Growth inhibitory activity) or anti-metastatic activity (particularly, metastatic lesion growth inhibitory activity)], killer activity induction promoting activity (particularly, killer activity induction promoting activity of intestinal lymphocytes), tumor cell recognition enhancing activity, interleukin Kin 12 (IL-12) gene expression enhancing activity, serum IAP level increasing activity, TGF- ⁇ (one of immunosuppressive substances) activity suppressing activity, and the like.
- antitumor activity for example, prolonging survival time in cancer-bearing individuals, antigen-tumorigenic activity (particularly, Growth inhibitory activity) or anti-metastatic activity (particularly, metastatic lesion growth inhibitory activity)
- the immunopotentiator of the present invention includes, for example, cancer, infectious diseases, autoimmune diseases, chronic fatigue syndrome, and lifestyle-related diseases.
- the glycoprotein of the present invention which is an active ingredient of the present invention, alone or preferably together with a usual carrier or diluent which is pharmaceutically or veterinarily acceptable, enhances immune enhancement.
- An effective amount can be administered to a subject in need thereof.
- glycoprotein of the present invention which is an active ingredient in the present invention, may be used for an immunoenhancing composition (preferably an immunoenhancing pharmaceutical composition), an immunoenhancing health food (preferably an immunoenhancing functional food), or an immunoenhancing composition.
- an immunoenhancing composition preferably an immunoenhancing pharmaceutical composition
- an immunoenhancing health food preferably an immunoenhancing functional food
- an immunoenhancing composition preferably an immunoenhancing composition
- the glycoprotein of the present invention which is an active ingredient in the stress load recovery promoting agent of the present invention, has a recovery promoting activity against stress load.
- Diseases to be treated or prevented by the agent for promoting recovery from stress of the present invention include, for example, cancer, infectious diseases, autoimmune diseases, chronic fatigue syndrome, and lifestyle-related diseases.
- glycoprotein of the present invention which is an active ingredient of the present invention, alone or, preferably, together with a common pharmaceutically or veterinarily acceptable carrier or diluent, can promote recovery from stress load.
- An effective amount can be administered to a subject in need thereof.
- glycoprotein of the present invention which is an active ingredient in the present invention, may be used as a composition for promoting recovery from stress (preferably, a pharmaceutical composition for promoting recovery from stress), or as a health food for promoting recovery from stress (preferably, Can be used to produce an oral hygiene composition for promoting the recovery from stress load.
- stress load recovery promotion activity refers to promoting recovery of immunity during immunity recovery after spontaneous recovery after release from stress load. Means activity.
- the timing of administration of the stress load recovery promoter of the present invention is not particularly limited as long as the immunity temporarily reduced by the stress load can be promoted by the administration, for example, before the stress load, During stress load and released from Z or stress load It can be administered during a later immune recovery phase.
- the “stress load recovery promoting activity” in the present invention is different from the mere “immune enhancing activity” found by the present inventors.
- the term “immune enhancing activity” refers to the state before administration (when the active ingredient having such activity is administered (immunity can be in a normal state in which immunity without stress is applied, In general, an activity in which immunity is improved as compared to immunity can be reduced due to load), and therefore, an activity that improves immunity itself.
- the “stress load recovery promoting activity” in the present invention is, as described above, an activity that promotes the recovery of immunity during the immunity recovery period, and therefore, an activity that improves the recovery speed of immunity. It is. When the agent for promoting recovery from stress load of the present invention is administered, the recovery speed of immunity is increased as compared with the case where the agent for promoting recovery from stress is not administered.
- the present invention when an active ingredient having such activity is administered, the immunity is directly improved, whereas If the glycoprotein of the present invention, which is an active ingredient in the stress load recovery promoting agent of the present invention, is administered to a subject animal in advance before stress is applied, the present invention provides a method of the present invention during stress loading and during immunity recovery. Even if the glycoprotein is not administered, the recovery of immunity is promoted in the immunity recovery phase. Also in this regard, the “immune enhancing activity” of the present invention and the “stress load recovery promoting activity” of the present invention are different activities.
- the glycoprotein of the present invention which is an active ingredient in the antitumor agent of the present invention, has antitumor activity.
- the antitumor activity is included in the immunopotentiating activity.
- the antitumor activity includes, for example, prolongation of survival time in cancer-bearing individuals, antigen-tumorigenic activity (particularly, primary tumor growth inhibitory activity), or anti-metastatic activity (particularly, metastatic focus growth inhibitory activity). Etc. are included.
- Cancers to be treated or prevented by the antitumor agent of the present invention include, for example, lung cancer, stomach cancer, liver cancer, colorectal cancer, spleen cancer, esophageal cancer, breast cancer, uterine cancer, uterine cancer, prostate cancer, sarcoma, melanoma Or leukemia.
- the glycoprotein of the present invention which is an active ingredient in the present invention, may be used alone or, preferably, together with a pharmaceutically or veterinarily acceptable ordinary carrier or diluent. It can be administered in effective amounts to subjects in need of treatment or prevention of tumors. Wear.
- glycoprotein of the present invention which is an active ingredient in the present invention, may be used as an antitumor composition (preferably an antitumor pharmaceutical composition), an antitumor health food (preferably an antitumor functional food), or an antitumor composition.
- an antitumor composition preferably an antitumor pharmaceutical composition
- an antitumor health food preferably an antitumor functional food
- an antitumor composition can be used for producing the oral hygiene composition of the present invention.
- the dosage form of the pharmaceutical composition of the present invention is not particularly limited, and examples thereof include powders, fine granules, granules, tablets, capsules, suspensions, emulsions, syrups, extracts, and powders.
- Oral preparations such as pills, or parenteral preparations such as injections, external solutions, ointments, suppositories, creams for topical administration, or eye drops.
- These oral preparations include, for example, sodium alginate, starch, corn starch, sucrose, lactose, glucose, mannitol, carboxymethylcellulose, dextrin, polybutylpyrrolidone, crystalline cellulose, soy lecithin, sucrose, fatty acid ester, Excipients, such as talc, magnesium stearate, polyethylene glycol, magnesium silicate, silica anhydride, or synthetic aluminum silicate, binders, disintegrants, surfactants, lubricants, fluidity promoters, diluents It can be manufactured according to a conventional method using a preservative, a coloring agent, a flavor, a flavoring agent, a stabilizer, a humectant, a preservative, an antioxidant and the like.
- parenteral administration methods include injection (subcutaneous, intravenous, etc.) and rectal administration. Of these, injections are most preferably used.
- a water-soluble solvent such as physiological saline or Ringer's solution
- a non-water-soluble solvent such as vegetable oil or fatty acid ester, glucose or sodium salt, etc.
- a tonicity agent, a solubilizing agent, a stabilizer, a preservative, a suspending agent, an emulsifier, or the like can be optionally used.
- the pharmaceutical composition of the present invention may be administered using a sustained-release preparation technique using a sustained-release polymer or the like.
- the pharmaceutical compositions of the present invention can be incorporated into a pellet of ethylene vinyl acetate polymer, and the pellet can be surgically implanted into the tissue to be treated or prevented.
- the pharmaceutical composition of the present invention contains, but is not limited to, the glycoprotein of the present invention in an amount of 0.01 to 99% by weight, preferably 0.1 to 80% by weight. be able to.
- the dosage when using the pharmaceutical composition of the present invention can be appropriately determined according to the type of disease, age, sex, weight, degree of symptoms, degree of symptoms, administration method, etc., and is orally or parenterally. It is possible to administer it in a controlled manner.
- the administration form is not limited to pharmaceuticals, and it can be provided in various forms, for example, a health food (preferably a functional food) or a feed as a food or drink.
- the food includes a beverage.
- human health in addition to (1) functions as nutrients (primary function) and (2) functions that appeal to the five senses of humans (secondary function), (3) human health, physical ability, or mental state (Tertiary function), for example, by regulating physiological systems such as the digestive system, circulatory system, endocrine system, immune system, or nervous system to maintain and restore health. It is known to have a positive effect.
- “healthy food” means a food that gives some effect on health or can be expected to have an effect
- “functional food” includes the above-mentioned “healthy food”.
- an oral hygiene composition for example, which is temporarily contained in the mouth, but is mostly given in the form of spitting out of the mouth, for example, in the form of a dentifrice, mouthwash, chewing gum, or gargle
- it can be given in the form of an inhalant for inhalation through the nose.
- an additive for example, a food additive
- the glycoprotein of the present invention can be added to desired food (including beverages), feed, dentifrice, mouthwash, chewing gum, gargle, etc. it can.
- TGF- Growth Factor-18
- the activity of promoting recovery of ⁇ cell activity against stress was evaluated by orally administering a sample for evaluation to mice for 10 days, applying a restraining stress for 18 hours, and measuring ⁇ cell activity after releasing the stress.
- a 50 mL cap-made polypropylene centrifuge tube Cat. No. 2341-050; Techno Glass Co., Ltd.
- mice Seven days after the release of the restraint stress, the mice were sacrificed, and the test was performed according to the following procedure according to the method of Greenberg et al. (Greenberg AH et al., J Exp Psychol, 12, 25-31, 1986). Natural killer (NK) cell activity was assessed by measuring lymph node cell cytotoxic activity against the NK-sensitive tumor cell line YAC-1 in vitro.
- Greenberg AH et al. J Exp Psychol, 12, 25-31, 1986.
- Natural killer (NK) cell activity was assessed by measuring lymph node cell cytotoxic activity against the NK-sensitive tumor cell line YAC-1 in vitro.
- the mouse spleen was aseptically removed from the mouse and transferred to a sterile Petri dish containing Hanks Balanced Salt Solution. After loosening the lymph nodes with scissors and tweezers, a single cell solution of lymphocytes was prepared through a mesh. After washing the cells three times with RPMI 1640 medium supplemented with 10% fetal calf serum (heat treatment at 56 ° C for 30 minutes), 2 OmmolZL of 4- (2-hydroxyethyl) -1-piperazineethanesulfone A cell suspension obtained by adjusting the cell concentration to 5 ⁇ 10 6 ZmL in RPMI 1640 medium supplemented with acid and 20 ⁇ g ZmL gentamicin was used as effector cells.
- YAC-1 cells used as target cells were cultured in RPMI1640 medium supplemented with 10% fetal bovine serum (heat treated at 56 ° C for 30 minutes), Kureha Chemical Industry Co., Ltd. It is the one that was maintained for the passage.
- Sodium chromate (Amersham Japan) was added to the YAC-1 cells and reacted at 37 ° C for 20 minutes. Unbound sodium radiochromate is washed three times with RPMI 1640 medium supplemented with 10% fetal calf serum (heat treated at 56 ° C for 30 minutes). Remove from this and remove 4 x 10 radioactive chromium-labeled tumor cells. Adjusted to ZmL.
- Bmax is the radioactivity of the maximum free group (unit).
- Bq Bq
- TGF-18 binding activity was evaluated by reacting a TGF-18 sample and a sample for evaluation in a test tube for 2 hours and then quantifying the bound TGF- by enzyme immunoassay.
- TGF-j8 sample (Funakoshi ) was dissolved in a phosphate buffer solution (pH 7.2) containing 2% albumin, and adjusted to a 100 ng / mL solution.
- the evaluation sample was dissolved in a phosphate buffer containing 2% albumin, and adjusted to a concentration of 2 mg / mL.
- the measurement was performed using a human TGF- ⁇ ELISA kit (Funakoshi).
- Example 2 Isolation of active fraction from dried powder of mycelium of Matsutake FERM BP-7304 strain)>
- Matsutake FERM BP Dry powder of mycelium of strain 7304 (Lot No .: M65T1Y1) 2. Put Og in a 500 mL Erlenmeyer flask, add 0.2 mol ZL sodium hydroxide lOOmL to this, and stir at 23 ° C. The bottom was extracted for 1 hour. After centrifugation (12000 rpm, 30 minutes, 4 ° C), the pH was adjusted to 7.0 with 1. OmolZL hydrochloric acid, and the supernatant (alkali extract) and precipitate (alkali extraction residue) were collected.
- aqueous layer powder was dissolved in 5 mL of 0.05 mol ZL-Tris hydrochloric acid buffer (pH 7.2), and getyl previously equilibrated with 0.05 mol ZL-Tris hydrochloric acid buffer.
- the above-mentioned fraction in the dialysis membrane of the B fraction was previously flattened with 0.05 mol ZL-Tris hydrochloric acid buffer.
- the mixture was applied to a equilibrated Sephacryl S-100 (Pharmacia) packed column ( ⁇ 16 mm, h300 mm), eluted with the same buffer, and fractionated using the absorbance at 280 nm as an index.
- the pattern shown in Fig. 2 was shown.
- the obtained fraction was divided into three, and the biological activity was measured. As a result, the activity was found in fraction B-1 (Fig. 3 and Table 3).
- Fraction B-1 was applied to a column ( ⁇ 16 mm, h600 mm) packed with Sephacryl S-500 (Pharmacia) pre-equilibrated with 0.05 mol ZL-Tris hydrochloric acid buffer, Elution was performed with the same buffer, and fractionation was performed using the absorbance at 280 nm as an index. As a result, the pattern shown in Fig. 4 was shown. The obtained fraction was divided into three, and the biological activity was measured. As a result, the activity was found in fraction B-1-2 (Table 4).
- Trisglycine' running buffer (Daiichi Kagaku)
- Electrophoresis conditions Electrophoresis was performed at 35 mA for 60 minutes.
- one spot was detected at a molecular weight of about 60 kDa.
- the acid hydrolysis was performed according to the following procedure. That is, 6.30 mg of PG was weighed, dissolved in 3.15 mL of pure water, and then filtered through a 0.22 m filter to obtain a solution of 2 mgZmL. 200 / zL of this solution was collected in a glass test tube, and evaporated to dryness under reduced pressure using an evaporator. Then, 200 L of 6 mol ZL hydrochloric acid was added thereto, and the mixture was hydrolyzed at 110 ° C. for 22 hours, and dried under reduced pressure with an evaporator to obtain a residue. The residue was dissolved in 100 L of pure water, and 50 L of the residue was used for amino acid analysis.
- Alkaline hydrolysis (for tributophan analysis) was performed according to the following procedure. That is, 1 mL of the PG solution (2 mg ZmL) was placed in an eppendorf tube, and dried under reduced pressure. Then, 4.2 mol ZL sodium hydroxide solution 100 / z L containing 5 mg of soluble starch (Starch Soluble) was added. . The tube was placed in a glass test tube and hydrolyzed at 110 ° C. for 16 hours under a vacuum tube. After air-cooling, open, cool the tube in ice, L was added and neutralized. Further, 420 ⁇ L of purified water was added to make a total amount of 500 ⁇ L, and 50 / z L thereof was used for amino acid analysis.
- the amino acid composition was aspartic acid and asparagine 9.65 mol%, threonine 6.15 mol%, serine 6.83 mol%, glutamic acid and glutamine 10.19 mol%, glycine 8.74 mol%, alanine 9 84 mol%, norin 6.94 mol%, 1 / 2-cystine 0.15 mol%, methionine 1.31 mol%, isoleucine 5.47 mol%, leucine 9.55 mol%, tyrosine 2.64 mol%, hueralanin 4 .09 mol%, lysine 4.99 mol%, histidine 1.97 mol%, arginine 5.00 mol%, tryptophan 1.17 mol%, and proline 5.33 mol%.
- CBB Coomassie Brilliant Blue
- N-terminal amino acid analysis using a gas phase sequencer was performed under the following conditions. That is, the sample was washed with 50% methanol Z0.1% trifluoroacetic acid (TFA) and methanol, dried, subjected to Edman degradation using the following equipment, and attempted to detect the amino acid sequence up to 8 residues from the N-terminal.
- TFA trifluoroacetic acid
- the sequence could not be determined.
- the measurements were performed under the conditions of 00-250 nm, cell length lmm, temperature at room temperature (23 ° C), and the number of integration was 8.
- Fig. 7 shows the obtained CD spectrum.
- PG 6.30 mg was weighed and dissolved in pure water 3.15 mU, and then filtered through a 0.22 m filter to obtain a 2 mg / mL solution.
- 500 L of this solution was collected in a glass test tube, and dried under reduced pressure using an evaporator.
- 200 mol of 2 mol / L trifluoroacetic acid was added to the mixture, and the mixture was hydrolyzed at 100 ° C. for 6 hours, and then dried under reduced pressure with an evaporator to obtain a residue.
- the residue was dissolved in 200 L of pure water, and further diluted 20 or 200 times with pure water.
- This solution 50 is supplemented with 500 ng of an internal standard substance heptose, and a high-speed column equipped with a column TSK-gel Sugar AXG 15 cm x 4.6 mm ID (Tosoichi) and a detector spectrophotometer RF-535 (Shimadzu Corporation)
- the liquid chromatograph LC 9A (Shimadzu Corporation) was applied.
- the column temperature was 70 ° C, the mobile phase and its flow rate were 0.5 mol / L potassium borate buffer (pH 8.7) and 0.4 mL Z min.
- the post-column labeling conditions used 1% arginine Z3% boric acid as the reaction reagent, the flow rate was 0.5 mL Z min, the reaction temperature was 150 ° C, and the detection wavelength was Ex32 Onm and EM430 nm.
- the neutral sugar composition of PG is, in descending order, glucose 561.45 ⁇ g / mg, mannose 16.66 ⁇ g Zmg, galatatoses 42.65 ⁇ g / mg, and fucose 9.57 ⁇ g Zmg. Was.
- xylose was below the detection limit.
- the column temperature was 60 ° C., and the mobile phase and its flow rate were 0.04 mol / L potassium borate buffer (pH 7.6) and 0.3 mL / min.
- the post-column labeling conditions used 1% arginine Z3% boric acid as the reaction reagent, the flow rate was 0.5 mL / min, the reaction temperature was 150 ° C, and the detection wavelength was Ex320nm and EM430nm.
- the amino sugar composition of PG was 0.36 gZmg of gnorecosamine. Mannosamine was below the detection limit (0.2 / z gZmg).
- FIG. 8 shows the obtained spectrum.
- glucose the main component of PG neutral sugar. That is, in 1 H NMR at 25 ° C., focusing on 4.5 ppm to 5.5 ppm characteristic of the proton at the 1-position of glucose, it is considered that the vicinity of 5.4 ppm and 5.2 ppm is the ⁇ 1 position of gnorecose.
- the minor peak (doublet peak) around 4.65 ppm is considered to be the j8 first place.
- 4.75ppm— 5.15ppm peak (4.79ppm peak at 45 ° C measurement) ) Are presumed to be derived from a protons of sugars and proteins other than glucose.
- a sample (hereinafter referred to as hydrazine-treated PG) was prepared by removing the protein moiety by hydrazine treatment. That is, PG was put into a test tube ( ⁇ 5 mm ⁇ h 50 mm), set in a hydragraph (Seikagaku Corporation), and vacuum dried at 50 ° C. for 5 hours. Next, 2 mL of anhydrous hydrazine was added and heated at 100 ° C. for 2 hours to perform gas phase hydrazine decomposition. Hydrazine was distilled off, the residue was dissolved in pure water (0.5 mL), and pure water was used as an external solution for dialysis.
- the dialysate solution was evaporated to dryness under reduced pressure using an evaporator, and used as a sample for NMR measurement.
- the measurement conditions were the same as in Example 3 (8) (i) except that the sample concentration was 7.7 mg / 2.5 mL.
- FIG. 9 shows the obtained spectrum.
- the 1 H NMR spectrum at 25 ° C. was broader than that of Example 3 (8) (i). This is considered to be because the protein disappeared by the hydrazine treatment and the polysaccharide concentration increased. Also, the large peak at 3.66 ppm observed in Example 3 (8) (i) was eliminated.
- the measurement conditions of 13 C NMR are as follows. That is, the observation frequency is 125.8 MHz, the reference is acetone (30.5 ppm), the temperature is 25 ° C, the observation width is 31.4 KHz, the data point is 128 K, the pulse width is about 45 °, and the pulse repetition time is The measurement was performed under the conditions of 4.0 seconds, 40,000 integration times, and complete decoupling.
- FIG. 10 shows the obtained spectrum. Since the sensitivity of 13 C NMR did not increase, the SZN ratio was insufficient and the analysis was difficult and powerful. The large peak at 60.7 ppm was presumed to be derived from components other than carbohydrates. Since the peaks at 65 ppm to 80 ppm were not uniform, the constituent sugars were estimated to be heterogeneous. The peak at 100. lppm is thought to be the ⁇ -form glucido bond at the 1-position carbon of glucose, supporting the 1 H NMR results.
- the chemical shift of the peak at 60 to 80 ppm was analyzed.
- the chemical shifts of glucose monosaccharide or disaccharide were analyzed, it was considered that the carbons at the 2-position and 4-position of glucose were linked by a daulside bond, and the bonding mode was estimated to be a12 or a14.
- FIG. 11 shows the obtained spectrum.
- 13 C NMR a spectrum in which the SZN ratio was slightly improved compared to Example 3 (8) (iii) was observed, and the chemical shift values were almost the same.
- the peak between 65 ppm and 80 ppm is not uniform !, which suggests that the sugar binding mode is heterogeneous.
- the peak at 100 ppm is probably the carbon at the 1-position of glucose, which is thought to be due to the ⁇ -form of the dullside bond, supporting the 1 H NMR results.
- Example 3 Except for the 1st position, the chemical shift of the peak between 60 ppm and 80 ppm was analyzed. Compared to the chemical shifts of the darcos monosaccharide or disaccharide, the possibility that the carbon at the 2- and 4-position of glucose is a glucide bond is considered as in Example 3 (8) (iii). The pattern was assumed to be ⁇ 1-2 or ⁇ 1-4.
- the PG carbohydrate moiety is completely diluted with methyl iodide in the presence of powdered sodium hydroxide to decompose the resulting methyli-dani polysaccharide into monosaccharides, and the resulting methyl-i-dani monosaccharide is subjected to reduced acetylation and partially methylated.
- the derivative was identified by gas chromatography (GC) and gas chromatography / mass spectrometry (GC / MS) measurement in the form of an acetyl derivative of sugar alcohol (partially methylated alditol acetate), and the composition ratio was determined.
- the obtained residue was washed 5 times with 2 mL of methanol, then added with 1 mL of a mixed solution of acetic anhydride and pyridine (1Z1), heated at 100 ° C. for 4 hours, and dried under reduced pressure with an evaporator.
- 2 mL of black-mouthed form was extracted by kneading, and further, 2 mL of pure water was added to knead to mix.
- 1.5 g of anhydrous sodium sulfate was added to the pore form layer, dried, and allowed to stand at room temperature for 30 minutes, followed by filtration to obtain a filtrate. The filtrate was evaporated to dryness under reduced pressure using an evaporator, dissolved in chloroform, and subjected to GC and MS analysis.
- GC-MS measurement conditions were as follows. That is, the GC analyzer was Hewlett-Packard HP5890 SERIES, the column liquid phase was SPB-5 (Spelco Japan), the column type was fused silica capillary 30mxO.25mm ID, the carrier gas was He, and the column temperature was 60 ° C ( The temperature was 280 ° C, the injection mode was FID, the injection volume was 0, and the injection mode was splitless.
- the MS uses a g [MS DX-303 mass spectrometer (JEOL) and a data processing system JMA DA5000 data processing system (JEOL), and the MS section uses the EI for the ionization method and the electron acceleration voltage for the 70V.
- the ionization current is 300 ⁇
- the ion source temperature is 250 ° C
- the ionization speed voltage is 3.
- Table 6 shows the results of identifying each peak on the chromatogram of the sample by comparing it with the standard mass spectrum of the partial methyl iodide alditol acetate. Further, Table 6 also shows the results of determining the composition ratio of the partial methyl alditol acetate from the area of each peak obtained in the gas chromatograph. These results suggested that the major linkage of PG sugar chain is 1 ⁇ 4 darcosyl.
- methyl oleate (GL Science Co., Ltd.) was weighed into a lOmL volumetric flask as a standard for quantification, and the form containing the internal standard was capped to the marked line to obtain a 2537 g ZmL standard solution. did. Further, this solution was diluted 25-fold with a black hole form containing an internal standard to prepare a 101.5 / zgZmL solution. Further, this was sequentially diluted 5-fold with a chloroform solution containing an internal standard to prepare a 20.3 / zgZmL solution, a 4.06 / zgZmL solution, and a 0.81 gZmL solution. As described below, these were subjected to GC analysis in the same manner as the sample solution, and a calibration curve was created from the obtained peak area and the concentration of the standard solution, from which the quantitative analysis of each fatty acid in the sample solution was performed. went.
- GC analysis was performed as follows. That is, a gas chromatograph HP5890 (Hewlett Packard) was used as an apparatus, a flame ionization detector (FID) was used as a detector, and SP238O (h3Omx O. 25 mm, film thickness 0.2 m) was used as a column. C (retained for 1 minute) ⁇ 250 ° C (temperature increased by + 8 ° CZ), inlet temperature 250 ° C, injection volume 1 ⁇ L (splitless injection). Since the GC analysis was performed using fatty acid methyl, the amount of fatty acid (as free fatty acid) in the sample was calculated according to the following equation.
- the fatty acid composition of PG in order of increasing strength, was 1.86 g Zmg of stearic acid (C18: 0), 1.84 ⁇ g / mg of olemitic acid (C16: 0), and oleic acid [C18: l ( 9)] l.52 / zg Zmg, linoleic acid [C18: 2 (9,12)] 0.94 gZmg and myristic acid (C14: 0) 0.55 ⁇ gZmg.
- Infrared spectroscopy was performed by the KBr method. More specifically, PGlmg and KBr powder 10mg were mixed homogeneously, pressed, molded into a disk shape, and measured using FTIR VAKOR-III type [Nippon Bunko Co., Ltd.]. Figure 12 shows the obtained IR ⁇ vector.
- PG was dissolved in pure water and measured at a concentration of 50 mgZmL.
- Bio Spec 1600 (Shimadzu Corporation) was used as an apparatus.
- Fig. 13 shows the obtained UV spectrum.
- C57BLZ6N mice purchased from Charles River Japan (Kanagawa) were subcutaneously implanted with 1 ⁇ 10 6 melanoma B16 / 0.2 mL Hanks balanced salt solution / animal subcutaneously in the axilla (6 mice per group).
- melanoma B16 is associated with tumors generated in the skin of C57BL / 6 mice.
- a tumor cell line (An NY Acad. Sci 100: 762-790, 1963).
- the tumor cell line was obtained from Tohoku University's Center for Medical and Aging Medical Resources (Storage No .: TKG0144), Kureha Chemical Co., Ltd. 'At the Institute of Biomedical Sciences, C57BLZ6N mice were subcultured and maintained subcutaneously in the axillary subcutaneous cells.
- Example 2 Twenty-four hours after the transplantation, PG (dissolved in physiological saline) obtained in Example 2 was intraperitoneally injected at a dose of 125 mgZkg or 250 mg / kg, 10 times every other day. As a control, 0.2 mL of physiological saline was used instead of the sample solution.
- plasma cell tumor X5563 is a tumor cell line (JNCI 24: 1153-1165, 1960) derived from a tumor developed in the ileocecal region of C3HZHe mouse. Obtained from the Attached Medical Cell Resource Center (storage number: TKG0174), and passaged and maintained in the abdominal cavity of C3HZHeN mice at Kureha Chemical Industry Co., Ltd.'s Biomedical Research Laboratory! / Puru cells were used.
- Example 2 Twenty-four hours after the transplantation, PG (dissolved in physiological saline) obtained in Example 2 was intraperitoneally injected at a dose of 125 mgZkg or 250 mg / kg, 10 times every other day. As a control, 0.2 mL of physiological saline was used instead of the sample solution.
- the daily survival for 60 days after transplantation was observed. (4Z6), and the survival rate was improved by the administration of the sample. Furthermore, in the surviving individuals, as shown in FIG. 15, the tumor size was clearly suppressed by the administration of the sample.
- sarcoma 180 Nippon Clea (Tokyo) Power 5 x 10-week-old female ICR mice were implanted with 1 ⁇ 10 6 /0.2 mL Hanks' balanced salt solution / animal subcutaneously under the axilla subcutaneously at 1 ⁇ 10 6 / Sarcoma 180 (S180). (10 animals per group).
- sarcoma 180 is a tumor cell line derived from sarcoma derived from albino mouse (Cancer
- mice Twenty-five days after transplantation, the mice were sacrificed, and tumor nodules were removed and weighed.
- the tumor nodule weight of the control group [mean standard error (SE)]: 1.05 ⁇ 0.22 g
- SE mean standard error
- Ehrlich carcinoma (Ehrlich) was implanted subcutaneously under the axillary area of a 5-week-old female ICR mouse purchased from Clair Japan (Tokyo) with 1 ⁇ 10 6 E. coli Z. 10).
- Ehrlich cancer is a tumor cell line (JNCI
- Example 13 1299-1377, 1953), and in this example, it was obtained from Tohoku University's Center for Aging and Medical Research, Medical Cell Resource Center (Storage No .: TKG0147), and at Kureha Chemical Co., Ltd. '
- the cells that were passaged and maintained in the abdominal cavity of ICR mice were used.
- Twenty-four hours after the transplantation PG (dissolved in physiological saline) obtained in Example 2 was intraperitoneally injected at a dose of 125 mgZkg or 250 mg / kg, 10 times every other day.
- 0.2 mL of physiological saline was used instead of the sample solution.
- mice Twenty-five days after transplantation, the mice were sacrificed, and tumor nodules were removed and weighed.
- the weight of tumor nodules in the control group (mean value SE) was 1.96 ⁇ 0.50 g, and the sample was 125 mgZkg.
- 250 mgZkg dose groups were 0.01 ⁇ 0. Olg and 0.48 ⁇ 0.33 g, respectively. Yes, administration of the sample clearly suppressed tumor growth.
- Yoshida sarcoma is a tumor cell line (Proc Imp Acad Tokyo 20: 611-618, 1944) derived from a tumor caused by applying o-aminoazotoluene for 3 months and applying arsenous acid alcohol.
- the average number of survival days in the control group was 8.3 ⁇ 0.3 days, compared with that of the 125 mgZkg and 250 mgZkg subjects They were 9.0 ⁇ 0.4 days and 7.5 ⁇ 1.1 days, respectively, and the survival tended to be prolonged by the administration of 125 mg Zkg of the sample.
- CDF1 mice purchased from Charles River Japan (Kanagawa) were subcutaneously implanted with 1 ⁇ 10 6 leukemia P388 Z rats with Z0.2 ml of Hanks' balanced salt solution (6 mice / group) under the axilla.
- Leukemia P388 is a tumor cell line derived from leukemia (Am J Pathol 33: 603, 1957) generated by treating DBA / 2 mice with methylcholanthrene.In this example, Tohoku University Obtained from the Medical Cell Resource Center attached to the Japan Institute of Gerontology (Storage No .: TKG0326) and used at the Kureha Chemical Industry Co., Ltd. 'In the biomedical laboratory, passaging and maintaining CDF1 mice intraperitoneally! did.
- Example 2 Twenty-four hours after the transplantation, PG (dissolved in physiological saline) obtained in Example 2 was injected intraperitoneally four times every other day in an amount of 125 mgZkg or 250 mgZkg. As a control, 0.2 mL of physiological saline was used instead of the sample solution.
- leukemia EL4 is a tumor cell line derived from lymphoma generated in the spleen of mice treated with dimethylbenzanthracene (DMBA) (Cancer Res 16: 338-343, 1956).
- DMBA dimethylbenzanthracene
- Example 2 TKG0150 attached to the Institute of Aging Medicine (Kyowa Chemical Industry Co., Ltd.), and maintained the cells maintained in the intraperitoneal cavity of C57BLZ6N mice at Kureha Chemical Industry Co., Ltd. used. Twenty-four hours after the transplantation, PG (dissolved in physiological saline) obtained in Example 2 was injected intraperitoneally four times every other day in an amount of 125 mgZkg or 250 mgZkg. As a control, 0.2 mL of physiological saline was used instead of the sample solution.
- the average survival time (mean value SE) of the control group was 12.0 ⁇ 0.4 days, and the samples were 125 mg / kg and 250 mg / kg. Those in the treatment group were 13.0 ⁇ 0.0 and 11.8 ⁇ 0.3, respectively. The survival period was prolonged by the administration of 125 mg Zkg of the sample.
- Hepatic cancer AH13 is a tumor cell line derived from a tumor generated in the liver by treating rats with dimethylaminoazobenzene (DAB) (Journal of the Japanese Society of Pathology 11: 147-168, 1967). University ⁇ Obtained from Medical Cell Resource Center attached to the Institute of Aging and Medical Sciences (Storage No .: TKG0011) and passaged and maintained in the intraperitoneal cavity of Donr yu rats at Kureha Chemical Industry Co., Ltd. Cells were used.
- DAB dimethylaminoazobenzene
- Example 2 Twenty-four hours after the transplantation, PG (dissolved in physiological saline) obtained in Example 2 was injected intraperitoneally four times every other day in an amount of 125 mgZkg or 250 mgZkg. As a control, instead of the sample solution was used with 0.2 mL of physiological saline.
- glycoprotein of the present invention can be applied to uses for an immunopotentiator, a stress load recovery promoter, and Z or an antitumor agent.
- FIG. 1 is a chromatograph showing an elution pattern obtained by performing anion exchange chromatography on an aqueous layer obtained by ChMe treatment of an alkali extract.
- FIG. 2 is a chromatograph showing an elution pattern obtained by performing gel filtration chromatography (Sephacryl S-100) on fraction B obtained by anion exchange chromatography.
- FIG. 3 is a graph showing the binding activity of TGF- ⁇ in each fraction obtained by performing gel filtration chromatography (Cefacryl S-100) on fraction B obtained by anion exchange chromatography.
- FIG. 5 is a chromatograph showing an elution pattern obtained by performing reverse-phase chromatography on fractions I-1-2 obtained by gel filtration chromatography (Sefacryl S-500).
- FIG. 6 is a photograph instead of a drawing which is a chromatograph and shows the result of performing SDS-polyacrylamide gel electrophoresis on the glycoprotein of the present invention obtained by reverse phase chromatography.
- FIG. 7 is a CD spectrum obtained by circular dichroism analysis of the glycoprotein of the present invention.
- FIG. 8 is a spectrum obtained by 1 H-dimensional NMR measurement of the glycoprotein of the present invention.
- FIG. 9 is a spectrum obtained by 1 H-dimensional NMR measurement of a hydrazine-treated glycoprotein.
- FIG. 10 is a spectrum obtained by 13 C-dimensional NMR measurement of the glycoprotein of the present invention.
- FIG. 11 is a spectrum obtained by 13 C-dimensional NMR measurement of a hydrazine-treated glycoprotein.
- FIG. 12 is a spectrum obtained by infrared spectroscopy of the glycoprotein of the present invention.
- FIG. 14 is a graph showing the survival rate of melanoma B16-transplanted mice to which the glycoprotein of the present invention has been administered.
- FIG. 15 is a graph showing time-dependent changes in tumor volume in plasmacytoma X5563 transplanted mice to which the glycoprotein of the present invention was administered.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04817163A EP1686136A4 (en) | 2003-10-14 | 2004-10-13 | NOVEL GLYCOPROTEIN AND MEDICINAL COMPOSITION CONTAINING THE SAME |
JP2005514633A JPWO2005035571A1 (ja) | 2003-10-14 | 2004-10-13 | 新規の糖タンパク質及びそれを含有する医薬組成物 |
US10/575,491 US20070066515A1 (en) | 2003-10-14 | 2004-10-13 | Novel glycoprotein and pharmaceutical composition containing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-353419 | 2003-10-14 | ||
JP2003353419 | 2003-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005035571A1 true WO2005035571A1 (ja) | 2005-04-21 |
Family
ID=34431157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/015057 WO2005035571A1 (ja) | 2003-10-14 | 2004-10-13 | 新規の糖タンパク質及びそれを含有する医薬組成物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20070066515A1 (ja) |
EP (1) | EP1686136A4 (ja) |
JP (1) | JPWO2005035571A1 (ja) |
WO (1) | WO2005035571A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001049308A1 (fr) * | 2000-01-05 | 2001-07-12 | Kureha Chemical Industry Co., Ltd. | Nouvelles compositions de renforcement de l'immunité |
WO2002030440A1 (fr) * | 2000-10-11 | 2002-04-18 | Kureha Chemical Industry Co., Ltd. | Compositions medicinales favorisant le retablissement d'une surcharge et nouvelle souche de champignon matsutake |
WO2003070264A1 (fr) * | 2002-02-22 | 2003-08-28 | Kureha Chemical Industry Co., Ltd. | Fraction adsorbee sur une resine echangeuse d'anions, immunopotentiateur et promoteur pour sa recuperation a partir du stress applique provenant du champignon matsutake |
US20040126392A1 (en) * | 2002-12-27 | 2004-07-01 | Kenichi Matsunaga | Cancer preventive agent and food |
US20040126393A1 (en) * | 2002-12-27 | 2004-07-01 | Tatsuo Suzuki | Infection preventive or therapeutic agent and food |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2767521B2 (ja) * | 1992-09-04 | 1998-06-18 | 農林水産省食品総合研究所長 | 新規抗腫瘍性蛋白質とその製造法および該蛋白質を有効成分として含有する抗腫瘍剤 |
-
2004
- 2004-10-13 US US10/575,491 patent/US20070066515A1/en not_active Abandoned
- 2004-10-13 JP JP2005514633A patent/JPWO2005035571A1/ja active Pending
- 2004-10-13 WO PCT/JP2004/015057 patent/WO2005035571A1/ja not_active Application Discontinuation
- 2004-10-13 EP EP04817163A patent/EP1686136A4/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001049308A1 (fr) * | 2000-01-05 | 2001-07-12 | Kureha Chemical Industry Co., Ltd. | Nouvelles compositions de renforcement de l'immunité |
WO2002030440A1 (fr) * | 2000-10-11 | 2002-04-18 | Kureha Chemical Industry Co., Ltd. | Compositions medicinales favorisant le retablissement d'une surcharge et nouvelle souche de champignon matsutake |
WO2003070264A1 (fr) * | 2002-02-22 | 2003-08-28 | Kureha Chemical Industry Co., Ltd. | Fraction adsorbee sur une resine echangeuse d'anions, immunopotentiateur et promoteur pour sa recuperation a partir du stress applique provenant du champignon matsutake |
US20040126392A1 (en) * | 2002-12-27 | 2004-07-01 | Kenichi Matsunaga | Cancer preventive agent and food |
US20040126393A1 (en) * | 2002-12-27 | 2004-07-01 | Tatsuo Suzuki | Infection preventive or therapeutic agent and food |
Non-Patent Citations (1)
Title |
---|
See also references of EP1686136A4 * |
Also Published As
Publication number | Publication date |
---|---|
US20070066515A1 (en) | 2007-03-22 |
JPWO2005035571A1 (ja) | 2007-11-22 |
EP1686136A4 (en) | 2006-12-20 |
EP1686136A1 (en) | 2006-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107163129B (zh) | κ-酪蛋白来源生物活性肽的制备和应用 | |
JP2009209151A (ja) | 新規免疫増強組成物 | |
JP4826696B2 (ja) | 血管新生阻害剤 | |
Ward et al. | Clinical experience of cancer immunotherapy integrated with oleic acid complexed with de-glycosylated vitamin D binding protein | |
EP0058093B1 (en) | Glycoprotein having anti-tumour and lectin-like activity | |
Xu et al. | Isolation, identification and molecular docking of anti-inflammatory peptides from walnut (Juglans regia L.) meal hydrolysates | |
JP4233029B2 (ja) | マイタケ由来の抽出物およびグリコプロテイン並びにその製造方法 | |
JP4681801B2 (ja) | 血管新生阻害剤およびその製造方法 | |
Wu et al. | Bioactive ingredients and medicinal values of Grifola frondosa (Maitake). Foods 2021; 10: 95 | |
WO2005035571A1 (ja) | 新規の糖タンパク質及びそれを含有する医薬組成物 | |
JP4448330B2 (ja) | マツタケ由来陰イオン交換樹脂吸着画分、免疫増強剤、及びストレス負荷回復促進剤 | |
WO2015197652A1 (fr) | Mannosylglycerate et ses derives pour utilisation en tant qu'agent immunostimulant | |
WO1991018617A1 (fr) | Medicament immunostimulant a base de glycopeptidolipides polaires de mycobacterium chelonae | |
JP4619352B2 (ja) | 胎児ヘモグロビン、細菌エンドトキシン、および任意でさらなる胎児肝成分を含む組成物 | |
JPWO2006030750A1 (ja) | 乳癌を抑制するカワリハラタケ抽出物 | |
JP2011168573A (ja) | フコキサンチン由来の免疫賦活剤、活性化酸素阻害剤又は血管新生抑制剤 | |
JP2018172296A (ja) | 焼酎蒸溜残液由来の新規環状テトラペプチド化合物 | |
JP2018172296A5 (ja) | ||
Bhardwaj et al. | A Comprehensive Review on Ganoderma lucidum derived Bioactive peptide Ling Zhi-8 | |
RU2765270C1 (ru) | Композиция растворимых мономерных и олигомерных фрагментов пептидогликана клеточной стенки грамотрицательных бактерий, способы ее получения и применения | |
JPH08208704A (ja) | 新規な糖タンパク質複合体、その製造方法、並びに抗腫瘍剤、免疫調節剤及び増殖因子阻害剤 | |
JP6837628B2 (ja) | 環状ジペプチドを含む抗歯周病原細菌剤 | |
WO2004061090A1 (ja) | ナチュラルキラー細胞を賦活化する作用を有する組成物及びその製造方法、及び前記組成物を使用して賦活化したナチュラルキラー細胞を含有する組成物及びその製造方法 | |
JP2022187488A (ja) | ヒメマツタケ菌糸体亜臨界水抽出物の製造方法 | |
JPWO2005027952A1 (ja) | 生体の免疫機構を通じて生理活性を発現する組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007066515 Country of ref document: US Ref document number: 2005514633 Country of ref document: JP Ref document number: 10575491 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004817163 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004817163 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004817163 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10575491 Country of ref document: US |